<DOC>
	<DOCNO>NCT02587065</DOCNO>
	<brief_summary>The primary objective study investigate whether Peg-IFN beta-1a improves satisfaction Relapsing-Remitting Multiple Sclerosis ( RRMS ) participant unsatisfied injectable subcutaneous Interferons , measure Abbreviated Treatment Satisfaction Questionnaire Medication ( TSQM-9 ) , 12 week . The secondary objective study evaluate study population : effect Peg-IFN beta-1a treatment participant ' satisfaction 24 week ; effect Peg-IFN beta-1a treatment short-term participant ' adherence ; effect Peg-IFN beta-1a treatment participant ' fatigue ; effect Peg-IFN beta-1a disease activity physical disability ; impact Peg-IFN beta-1a treatment participant-reported health-related quality life ; impact Peg-IFN beta-1a treatment participant ' injection-system satisfaction ; Evaluate relationship participant ' satisfaction adherence ; Evaluate relationship participant ' satisfaction social-demographic factor ( age , sex , employment working , level education , etc ) clinical characteristic ( annualized relapse rate [ ARR ] , disability , etc . ) evaluate treatment safety tolerability .</brief_summary>
	<brief_title>Plegridy Satisfaction Study Participants</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Subjects diagnose Relapsing Remitting MS accord 2010 McDonald criterion . Subjects EDSS score 0.0 5.0 baseline . Key Pregnancy breastfeed . Have contraindication treatment PegIFNbeta 1a accord Summary Product Characteristics . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>